Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
- Market Reaction: Vaccine maker stocks fell Friday morning after president-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
- Controversial Pick: Kennedy has a history of raising unfounded concerns about vaccine safety. His nomination still requires Senate confirmation.
- Stocks Down: Shares of Pfizer, Eli Lilly, and other pharmaceutical firms declined in early trading.
Key Takeaways
Vaccine Stocks Slide as RFK Jr. Tapped for HHS Post
In a move shaking up both politics and markets, President-elect Donald Trump announced Thursday his intent to nominate Robert F. Kennedy Jr. as Secretary of Health and Human Services. Kennedy, who briefly ran as a third-party candidate before endorsing Trump, has long questioned vaccine safety raising concerns among investors.
The announcement triggered a selloff in vaccine maker stocks Friday morning, with shares of Pfizer, Eli Lilly, and others declining as markets reacted to the potential policy shift.
Vaccine Makers Slide Across U.S. and Global Markets
- U.S. Pharma Stocks Down: Shares of Pfizer (PFE), Eli Lilly (LLY), and Novavax (NVAX) fell in early Friday trading.
- Global Declines: International firms with U.S. exposure—AstraZeneca (AZN), BioNTech (BNTX), and Novo Nordisk (NVO)—also saw declines.
- Market Context: The selloff followed political developments tied to vaccine oversight and regulatory leadership.
Why RFK Jr.’s HHS Nomination Is Weighing on Vaccine Stocks
President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services has rattled investors in vaccine makers. Kennedy, a former environmental lawyer, has long promoted discredited theories about vaccine safety including the false claim that vaccines cause autism and has criticized pharmaceutical influence over federal regulators.
His pledge to “free the agencies from the smothering cloud of corporate capture” has raised concerns about potential shifts in regulatory tone. Shares of Pfizer, Eli Lilly, Novavax, AstraZeneca, BioNTech, and Novo Nordisk all declined following the announcement.
Kennedy’s confirmation still requires Senate approval, which could prove contentious even with a Republican majority due to his history of extreme statements.
